MediPharm Labs Corp. (TSX:LABS)

MediPharm Labs Balance Sheet

Financials in millions CAD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	9.85	10.81	11.69	17.98	24.15	34.11
Short-Term Investments	0.57	0.56	0.19	0.27	0.76	1.14
Cash & Short-Term Investments	10.42	11.37	11.88	18.25	24.9	35.25
Cash Growth	-2.10%	-4.27%	-34.92%	-26.73%	-29.36%	60.46%
Accounts Receivable	6.71	6.77	6.88	5.52	12.35	15.72
Other Receivables	0.57	0.76	0.63	0.35	0.66	1.2
Receivables	7.27	7.53	7.51	5.87	13.01	16.92
Inventory	9.67	7.85	8.56	9.89	7.78	10.98
Prepaid Expenses	0.63	0.34	0.42	0.64	0.69	1.06
Other Current Assets	0.45	0.38	4.71	2	0.98	1.34
Total Current Assets	28.44	27.47	33.08	36.63	47.35	65.55
Property, Plant & Equipment	16.97	17.6	19.16	25.27	18.11	25.89
Other Intangible Assets	0.59	0.68	0.85	1.03	0.04	0.04
Other Long-Term Assets	-	-	0.64	1	-	0.88
Total Assets	45.99	45.74	53.73	63.94	65.5	92.36

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	5.61	4.72	4.24	2.13	3.54	2.99
Accrued Expenses	3.28	3.73	4.49	4.91	3.67	4.14
Short-Term Debt	0.41	0.15	0.26	2.11	0.52	-
Current Portion of Leases	0.01	0.05	0.08	0.12	0.08	0.11
Current Unearned Revenue	0.57	0.57	0.61	0.39	0.49	1.32
Other Current Liabilities	0.68	0.71	0.83	1.21	1.15	0.31
Total Current Liabilities	10.56	9.93	10.5	10.86	9.46	8.88
Long-Term Leases	-	-	0.05	0.07	0.03	0.1
Long-Term Unearned Revenue	-	-	-	-	-	0.23
Other Long-Term Liabilities	-	-	-	-	-	0
Total Liabilities	10.56	9.93	10.55	10.93	9.49	9.22

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	202.07	201.9	201.21	200.24	191.26	190.55
Retained Earnings	-170.24	-169.38	-187.43	-176.73	-163.65	-129.34
Comprehensive Income & Other	3.6	3.29	29.4	29.49	28.4	21.94
Total Common Equity	35.43	35.81	43.18	53.01	56.01	83.15
Shareholders' Equity	35.43	35.81	43.18	53.01	56.01	83.15
Total Liabilities & Equity	45.99	45.74	53.73	63.94	65.5	92.36

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	0.42	0.2	0.39	2.3	0.63	0.22
Net Cash (Debt)	10	11.17	11.49	15.95	24.27	35.04
Net Cash Growth	-1.01%	-2.79%	-27.99%	-34.27%	-30.73%	897.86%
Net Cash Per Share	0.02	0.03	0.03	0.04	0.09	0.14
Filing Date Shares Outstanding	427.18	424.86	415.14	404.05	282.16	273.94
Total Common Shares Outstanding	427.18	424.86	415.05	401.4	282.16	273.54
Working Capital	17.88	17.54	22.59	25.77	37.89	56.67
Book Value Per Share	0.08	0.08	0.10	0.13	0.20	0.30
Tangible Book Value	34.85	35.14	42.33	51.97	55.97	83.1
Tangible Book Value Per Share	0.08	0.08	0.10	0.13	0.20	0.30
Land	1.86	1.86	1.86	2.81	1.52	1.86
Buildings	24.97	24.97	24.97	27.84	20.93	24.79
Machinery	14.62	14.59	15.1	18.24	17.46	18.88
Construction In Progress	0.03	0.01	0.05	2.5	2.6	4.49
Leasehold Improvements	0.21	0.21	0.21	0.21	0.21	0.21

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 29, 2026

Data Sources Report a data error